Happened in AI

NewsMedicine

FDA comment period on generative AI medical devices closes; hospital group asks for clearer risk rules

Public comments on the FDA's discussion paper about regulating generative AI medical devices closed on 19 October, with hospitals asking for clearer risk and labeling rules; the paper is not guidance and binds no one.

Evidence: 5 sources · 3 official records · 2 independent reports · 3 open questions

By Happened in AI Editors

Published
Read
2 min
Timeline of the FDA generative AI device discussion paper, August to October 2026 FDA discussion paper on generative AI devices Docket FDA-2026-N-7874. A discussion paper, not guidance. 18 AUG 2026 Paper published Comments invited 19 OCT 2026 AHA files comments Comment period closes NEXT Not announced Guidance? Timing? Sources: FDA announcement, 18 August 2026; American Hospital Association, 19 October 2026.
The FDA's generative AI discussion paper, from publication to the close of comments. Source: FDA; American Hospital Association. Happened in AI · Original graphic

What happened

  • On 18 August, the FDA's Digital Health Center of Excellence published a discussion paper, "Considerations for the Regulation of Generative AI-Enabled Medical Devices", under docket FDA-2026-N-7874.
  • The comment period closed on 19 October.
  • The paper sketches a risk approach along two axes, what a device's output does (from information to autonomous action) and how severe the harm could be if that output is wrong.
  • On 19 October, the American Hospital Association filed comments supporting a flexible, risk-based framework and asking for clearer labeling and disclosure rules.

Why it matters

Chatbots and other generative AI tools are moving into clinical and patient-facing use, and current device rules were written for software that does not change its answers. The responses to this docket are likely to shape how the FDA approaches these products.

What is confirmed and what is claimed

Confirmed

  • The discussion paper was released on 18 August with comments due 19 October (FDA announcement; regulations.gov docket; also reported by MD+DI and Applied Clinical Trials). 235
  • The paper is not draft or final guidance and proposes no binding policy changes (described this way in law-firm and trade-press summaries of the paper).
  • The AHA submitted comments on 19 October recommending the FDA refine its proposed risk heuristic, issue labeling guidance, and clarify which applications fall outside device oversight (AHA letter and news release; also reported by Becker's Hospital Review). 4
  • Other groups filed comments, including the neurosurgeons' organizations AANS and CNS (AANS advocacy page).

Claimed, not independently verified

  • The AHA says hospitals cannot see enough of how AI tools work inside, and that bias, hallucinations, and model drift are not fully addressed by existing device frameworks.
  • The neurosurgeons' groups argue that risk should be judged by the accuracy and clinical consequences of a tool's outputs, not only by the type of activity it performs.

The FDA has spent years clearing AI software that reads scans or flags abnormal heart rhythms. Those tools usually give a fixed kind of output. Generative AI tools are different: they write free text, can answer the same question in different ways, and are often built on general-purpose foundation models that the device maker did not train. The August discussion paper is the agency's first broad attempt to ask how its device rules should handle them.

Context

The paper asks questions instead of setting rules. It suggests weighing two things together: how directive a tool's output is, from background information up to taking an action on its own, and how bad the result could be if the output is wrong. Summaries note that patient-facing tools may sit higher on the risk scale, because patients are less able to catch mistakes, and that a "talk to your doctor" disclaimer does not make a directive output less directive. The paper also raises foundation models and agentic systems.

Being regulated as a device, or cleared by the FDA, is not evidence that a tool helps patients. Our guide to reading AI medicine news explains the difference.

What to watch

  • Whether the FDA publishes a summary of the comments, or moves to draft guidance.
  • How the agency treats administrative and clinical decision support tools that commenters want kept outside device oversight.
  • Coordination with other regulators, including the UK's MHRA, which is reworking its own AI device rules.

What we don’t know yet

  • How many comments the docket received in total; one tracker counted 123 by September, before the deadline.
  • Whether the FDA will follow the discussion paper with draft guidance, and on what timeline.
  • Whether the agency believes its current legal authority covers the approaches in the paper, which the paper itself does not address.

Evidence and sources

  1. Regulatory record FDA Seeks Public Feedback to Inform Regulatory Approach for Generative AI-Enabled Medical Devices US Food and Drug Administration ·
  2. Document or data Considerations for the Regulation of Generative AI-Enabled Medical Devices (docket FDA-2026-N-7874) Regulations.gov
  3. Primary announcement AHA Provides Feedback to FDA on Regulatory Considerations for Generative AI-Enabled Medical Devices American Hospital Association ·
  4. Independent reporting Hospitals can't see inside AI tools, AHA tells FDA Becker's Hospital Review
  5. Independent reporting FDA Opens Comment Period on GenAI Device Regulation MD+DI